ClinicalTrials.gg
CompletedNCT06214741Updated Apr 30, 2026

A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight

A Phase 3 interventional study of survodutide and Placebo matching BI 456906 in Obesity and Overweight, sponsored by Boehringer Ingelheim. Completed at 28 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2025, 1 year 3 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Apr 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
307
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing survodutide in Obesity — 4 open to participants now, 7 under way, 3 of them phase 3. survodutide · Obesity.

Enrollment
8th of 22
307 · median 121
Started
2024
with 7 others
Phase 3
9 of 22
3 open now
Registered
11th of 22
by date
Lead sponsor
22 of 22
Boehringer Ingelheim

Among the 22 studies testing survodutide in Obesity, this one is the 8th largest by enrollment, is one of 8 that started in 2024, is one of 9 in phase 3, and was the 11th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 22 studies testing survodutide in Obesity are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About survodutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing survodutide in Obesity, or all of them as a file.
02

Study summary

This study in China is open to adults who are at least 18 years old who are living with overweight or obesity. People with a body mass index (BMI) of 28 kg/m\^2 or higher or 24 kg/m\^2 or higher with at least 1 weight related problem can join the study. The main purpose of this study is to find out whether a medicine called survodutide helps people with overweight or obesity. 2 different doses of survodutide are tested in this study.

Participants are put into 3 groups by chance. Each participant has an equal chance of being in each group. 2 groups get different doses of survodutide. 1 group gets placebo. Participants get survodutide or placebo as injections under the skin once a week for about 19 months.

Placebo injections look like survodutide injections but do not contain any medicine.

Participants are in the study for about 21 months. During this time, there are 20 visits. 14 visits are in person at the study site. Where possible, 6 visits can be done by video call, or by phone in rare cases. During this time, doctors regularly measure participant's body weight. Results are compared between the survodutide groups and placebo group to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

03

Conditions studied

  • Obesity
  • Overweight
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, age ≥18 years at the time of signing .
  2. (BMI) ≥28 kg/m\^2 at screening, OR BMI ≥24 kg/m\^2 at screening with the presence of at least one of the following weight-related complications:

    • Hypertension (defined as repeated, i.e. at least 3 measurements in resting condition, systolic blood pressure (SBP) values of ≥140 mmHg and/or diastolic blood pressure (DBP) values of ≥90 mmHg in the absence of anti-hypertensive treatment, or intake of at least 1 anti-hypertensive drug to maintain a normotensive blood pressure)
    • Dyslipidaemia (defined as at least 1 lipid-lowering treatment required to maintain normal blood lipid levels, or low density lipoprotein (LDL) cholesterol ≥160 mg/dL (≥4.1 mmol/L), or triglycerides ≥150 mg/dL (≥1.7 mmol/L), or high density lipoprotein (HDL) cholesterol \<40 mg/dL (\<1.0 mmol/L) for men or HDL cholesterol \<50 mg/dL (\<1.3 mmol/L) for women)
    • Obstructive sleep apnoea
    • Cardiovascular disease (CVD) (e.g. heart failure (HF) with (NYHA) functional class II-III, history of ischaemic or haemorrhagic stroke or cerebrovascular revascularisation procedure [e.g. carotid endarterectomy and/or stent], myocardial infarction (MI), coronary artery disease, or peripheral vascular disease)
    • Type 2 diabetes mellitus (T2DM) diagnosed at least 180 days prior to screening (glycosylated (HbA1c) ≥6.5% (48 mmol/mol) and \<10% (86 mmol/mol), and fasting plasma glucose (FPG) ≤11.1 mmol/L measured by the central laboratory at screening

      --- Currently treated with either: diet and exercise alone or stable treatment (for at least 3 months prior to screening) with metformin, sodium-glucose cotransporter-2 inhibitor (SGLT2i) inhibitor, acarbose, sulfonylurea, or glitazone as single agent therapy, or up to 3 anti-hyperglycaemia medications (metformin, SGLT2i, acarbose, sulfonylurea, or glitazone) according to local label

    • Non-alcoholic steatohepatitis (NASH), as assessed in medical records by histological liver assessment (within the last 6 months)
  3. History of at least one self-reported unsuccessful dietary effort to lose body weight
  4. Signed and dated written informed consent in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial
  5. Woman of (WOCBP) must be ready and able to use highly effective methods of per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria and instructions on the duration of their use will be provided in the participant information.

Further inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

(A) Obesity:

  1. Body weight change (self-reported) >5% within 3 months before screening.
  2. Treatment with any medication for the indication obesity within 3 months before screening.
  3. Previous or planned (during the trial period) treatment for obesity with surgery or a weight loss device, or prior surgery of the GI tract that could interfere with body weight The following are allowed: (1) liposuction and/or abdominoplasty, if performed >1 year before screening, (2) lap banding, if the band has been removed >1 year before screening, (3) intragastric balloon, if the balloon has been removed >1 year before screening, (4) duodenal-jejunal bypass sleeve, if the sleeve has been removed >1 year before screening, (5) appendectomy, (6) simple hernia repair, or (7) cholecystectomy
  4. Have obesity induced by other endocrinologic disorders (for example, Cushing Syndrome) or diagnosed monogenetic or syndromic forms of obesity (for example, melanocortin 4 receptor deficiency, leptin deficiency, or Prader Willi Syndrome) (B) Diabetes-related for participants with T2DM:
  5. Treatment with any medication for the indication of T2DM other than stated in the inclusion criteria within 3 months before screening (i.e. insulin, amylin analogues, glucagon-like peptide-1 receptor (GLP- 1R)) agonists, GLP-1R agonist/insulin/glucose-dependent insulinotropic polypeptide (GIP) combinations, and dipeptidyl peptidase 4 inhibitor (DPP-4i))
  6. New initiation of any other glucose-lowering drug within 3 months prior to screening for this trial
  7. Uncontrolled and potentially unstable diabetic retinopathy or maculopathy, verified by an eye examination within 3 months prior to screening or in the period between screening and randomisation Further exclusion criteria apply.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
307 participants (actual)

Study arms

  • Experimental
    survodutide 3.6 mg

    Drug: survodutide

  • Experimental
    survodutide 4.8 mg

    Drug: survodutide

  • Placebo comparator
    Placebo

    Drug: Placebo matching BI 456906

Interventions

  • once weekly subcutaneous injection

    Also known as: BI 456906

  • DrugPlacebo matching BI 456906

    Once weekly subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Percentage change in body weight from baseline to Week 52

    Time frame: At baseline and at Week 52.

  2. Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 52

    Time frame: At baseline and at Week 52.

Secondary outcomes

  1. Key secondary endpoint: Achievement of body weight reduction ≥10% (yes/no) from baseline to Week 52

    Time frame: At baseline and at Week 52

  2. Key secondary endpoint: Achievement of body weight reduction ≥15% (yes/no) from baseline to Week 52

    Time frame: At baseline and at Week 52

  3. Key secondary endpoint: Absolute change from baseline to Week 52 in waist circumference (cm)

    Time frame: At baseline and at Week 52

  4. Achievement of body weight reduction ≥20% (yes/no) from baseline to Week 52

    Time frame: At baseline and at Week 52

  5. Absolute change from baseline to Week 52 in body weight (kg)

    Time frame: At baseline and at Week 52

  6. Absolute change from baseline to Week 52 in glycosylated haemoglobin A1c (HbA1c) (%)

    Time frame: At baseline and at Week 52

  7. Absolute change from baseline to Week 52 in HbA1c (mmol/mol)

    Time frame: At baseline and at Week 52

  8. Absolute change from baseline to Week 52 in systolic blood pressure (SBP) (mmHg)

    Time frame: At baseline and at Week 52

  9. Absolute change from baseline to Week 52 in diastolic blood pressure (DBP) (mmHg)

    Time frame: At baseline and at Week 52

  10. Absolute change from baseline to Week 52 in body mass index (BMI) (kg/m^2)

    Time frame: At baseline and at Week 52

  11. Absolute change from baseline to Week 52 in fasting plasma glucose (FPG) (mg/dL)

    Time frame: At baseline and at Week 52

  12. Absolute change from baseline to Week 52 in fasting plasma insulin (FPI) (mIU/L)

    Time frame: At baseline and at Week 52

  13. Absolute change from baseline to Week 52 in total cholesterol (mg/dL)

    Time frame: At baseline and at Week 52

  14. Absolute change from baseline to Week 52 in high-density lipoprotein (HDL) cholesterol (mg/dL)

    Time frame: At baseline and at Week 52

  15. Absolute change from baseline to Week 52 in low-density lipoprotein (LDL) cholesterol (mg/dL)

    Time frame: At baseline and at Week 52

  16. Absolute change from baseline to Week 52 in very low-density lipoprotein (VDL) cholesterol (mg/dL)

    Time frame: At baseline and at Week 52

  17. Absolute change from baseline to Week 52 in triglycerides (mg/dL)

    Time frame: At baseline and at Week 52

  18. Absolute change from baseline to Week 52 in free fatty acids (mg/dL)

    Time frame: At baseline and at Week 52

  19. Absolute change from baseline to Week 52 in alanine aminotransferase (ALT) (U/L)

    Time frame: At baseline and at Week 52

  20. Absolute change from baseline to Week 52 in aspartate aminotransferase (AST) (U/L)

    Time frame: At baseline and at Week 52

07

Study locations

28 sites
  • Beijing Chao-Yang Hospital
    Beijing, 100020, China
  • Peking University People's Hospital
    Beijing, 100044, China
  • Beijing Pinggu Hospital
    Beijing, 101200, China
  • The First Hospital of Jilin University
    Changchun, 130021, China
  • The Second Hospital of Jilin University
    Changchun, 130041, China
  • Changzhou Second People's Hospital
    Changzhou, 213004, China
  • People's Hospital of Sichuan Province
    Chengdu, 610072, China
  • Second Affiliated Hospital Chongqing Medical University
    Chongqing, 400016, China
  • NanFang Hosptial
    Guangzhou, 510515, China
  • Forth Clinical Hospital of Harbin Medical University
    Harbin, 150599, China
  • Huzhou Central Hospital
    Huzhou, 313000, China
  • Center Hospital of Jinan
    Jinan, 250013, China
  • Jincheng General Hospital
    Jincheng, 048000, China
  • Lishui Municipal Central Hospital
    Lishui, 323020, China
  • The First Affiliated Hospital of Henan University of Science and Technology
    Luoyang, 471000, China
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, 210011, China
  • Affiliated Hospital of Nantong University
    Nantong, 226001, China
  • The First Affiliated Hospital of Ningbo University
    Ningbo, 315010, China
  • Panjin Liao Oil Gem Flower Hospital
    Panjin, 124000, China
  • Shanghai Fifth People's Hospital affiliated to Fudan University
    Shanghai, 200240, China
  • Siping Central People's Hospital
    Siping, 136000, China
  • Tianjin Medical University Chu Hisen-I Memorial Hospital
    Tianjin, 300070, China
  • Tianjin Medical University General Hospital
    Tianjin, 30052, China
  • Wuhan Union Hospital
    Wuhan, 430022, China
  • The First Affiliated Hospital of Xi'an Medical University
    Xi'an, 710077, China
  • The People's Hospital Of Xuancheng City
    Xuancheng, 242000, China
  • Yichang Central People's Hospital
    Yichang, 443000, China
  • Yueyang People's Hospital
    Yueyang, 414109, China
08

References and documents

Related links

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.mystudywindow.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Jul 2025, 17 months.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 17 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2024
First posted
Jan 22, 2024
StartActual
Feb 6, 2024
Primary completionActual
Jul 29, 2025
CompletionActual
Jan 28, 2026
Results delay requested
Apr 22, 2026
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06214741
Responsible party
Sponsor
First posted
Jan 22, 2024
Start date
Feb 6, 2024
Primary completion
Jul 29, 2025
Completion
Jan 28, 2026
Last update
Apr 30, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Survodutide

Start the discussion